Document is current

Article History

Received: 15 February 2024

Revised: 5 June 2024

Accepted: 10 June 2024

First Online: 20 June 2024

Competing interests

: EC has acted as a consultant of ENTOS Inc., and has received research funds from ERASCA, InnoCare Pharma, and Prelude. GH has served as an advisor to AstraZeneca, Bayer, Lilly, BMS, Merck, and MSD, and has received honoraria from AstraZeneca, Bayer, Lilly, and MSD. ET has received funding from Astrazeneca. ET has gotten consulting fees from Astrazeneca and Menarini. MR received travel expenses reimbursement from Sanofi. CZ, NK, RL, HX, and JZ are full-time employees of InnoCare Pharma. AB reports personal fees from Guardant Health as well as grants from AstraZeneca, Boehringer-Ingelheim and Neophore. AB is also a shareholder of Neophore and Kither. AD received honoraria from 14ner/Elevation Oncology, Amgen, Abbvie, ArcherDX, AstraZeneca, Beigene, BergenBio, Blueprint Medicines, Bristol Myers Squibb, Boehringer Ingelheim, Chugai Pharmaceutical, EcoR1, EMD Serono, Entos, Exelixis, Helsinn, Hengrui Therapeutics, Ignyta/Genentech/Roche, Janssen, Loxo/Bayer/Lilly, Merus, Monopteros, MonteRosa, Novartis, Nuvalent, Pfizer, Prelude, Regeneron, Repare RX, Springer Healthcare, Takeda/Ariad/Millenium, Treeline Bio, TP Therapeutics, Tyra Biosciences, Verastem. AD also served as Advisory Board member for Bayer, MonteRosa, Abbvie, EcoR1 Capital, LLC, Amgen, Helsinn, Novartis, Loxo/Lilly, and AnHeart Therapeutics and as a consultant for MonteRosa, Innocare, Boundless Bio, Treeline Bio, Nuvalent, 14ner/Elevation Oncology, Entos, Prelude, and Zymeworks. AD obtained research funds from Foundatin Medicine, GlaxoSmithKlein, Teva, Taiho, PharmaMar, equity funds from mBrace, and royalties from Wolters Kluwer; Other (Food/Beverage): Merck, Puma, Merus, Boehringer Ingelheim; CME Honoraria: Answers in CME, Applied Pharmaceutical Science, Inc, AXIS, Clinical Care Options, Doc Congress, EPG Health, Harborside Nexus, I3 Health, Imedex, Liberum, Medendi, Medscape, Med Learning, MedTalks, MJH Life Sciences, MORE Health, Ology, OncLive, Paradigm, Peerview Institute, PeerVoice, Physicians Education, Projects in Knowledge, Resources, Remedica Ltd, Research to Practice, RV More, Targeted Oncology, TouchIME, WebMD. AD has also filed a copyright for Selpercatinib-Osimertinib (pending).

: Animal experiments were conducted in compliance with the national guidelines and were approved by both the University of Miami and MSKCC.

: All authors have read and agreed to the submitted version of the manuscript.